Answers are grounded in this paper and cite their sources.
Fibroblast activation protein (FAP) is a new promising molecular target for theragnostic approach. FAP inhibitors (FAPIs) labeled with 177Lu could be potentially a therapeutic radiopharmaceutical. Here, we presented the experience of 4 cycles of 177Lu-FAPI in a 67-year-old man with an unresectable mediastinal sarcoma.
No takes yet. Share an insight, caveat, or question.
Banihashemian et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: